Quidel Corp (NASDAQ: QDEL) reported Q4 EPS of $0.37, $0.28 better than the analyst estimate of $0.09. Revenue for the quarter came in at $63.6 million versus the consensus estimate of $61.05 million.

"We continue to be pleased with the progress we are making as a company. We rebounded from a slow start to the year and realized a very strong fourth quarter, due in part to market share gains with our Sofia Influenza A+B product, and the largest number of Sofias placed in any quarter since launch," said Douglas Bryant, president and CEO of Quidel Corporation. "Additionally, we received CLIA waiver of Sofia Strep A+ in December, which provides another key opportunity to grow the total number of Sofia installations well beyond our initial goal of 10,000 units running our initial menu of assays."

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.